Clene Nanomedicine

About:

Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.

Website: https://clene.com/

Twitter/X: clenenano

Top Investors: National Institutes of Health, National Multiple Sclerosis Society (NMSS), FightMND, Maryland Department of Housing and Community Development, SymBiosis LLC

Description:

Clene Nanomedicine is a clinical-stage biopharmaceutical company that focuses on the development of unique therapeutics for neurodegenerative diseases. The company innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.

Total Funding Amount:

$190M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Salt Lake City, Utah, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)clenenanomedicine.com

Founders:

Mark Mortenson

Number of Employees:

51-100

Last Funding Date:

2024-09-30

IPO Status:

Public

Industries:

© 2025 bioDAO.ai